The Discovery of THCP and Its Place in Cannabinoid Research

Research into the chemical constituents of Cannabis sativa has progressed in measured steps over decades. The isolation of delta-9-tetrahydrocannabinol, commonly known as THC, in 1964 provided the foundation for understanding the plant's psychoactive properties. Subsequent work identified dozens of related phytocannabinoids. In late 2019, a team of Italian researchers reported the presence of a new homolog in a medicinal cannabis variety. They named it delta-9-tetrahydrocannabiphorol, or THCP. This compound features a seven-carbon alkyl side chain rather than the five-carbon chain found in THC.

The 2019 study, published in Scientific Reports, demonstrated that THCP binds to the human CB1 receptor with markedly higher affinity than THC. Its inhibition constant measured 1.2 nanomolar compared with approximately 40 nanomolar for THC. In mouse behavioral tests known as the cannabinoid tetrad, THCP produced stronger effects on locomotion, pain response, catalepsy, and body temperature. These findings established THCP as a full agonist at cannabinoid receptors with greater potency in laboratory models.

Potency and the Limits of Existing Evidence

Claims that THCP is up to thirty-three times more potent than THC originate from receptor-binding assays rather than direct comparisons of effects in people. Receptor affinity does not translate linearly into human experience, yet the difference remains substantial enough to warrant caution. No controlled clinical trials in humans have examined THCP safety, dosing, or adverse outcomes. All available information on human effects therefore rests on preclinical data, limited case reports, and user observations.

It does not follow, however, that the absence of large-scale trials means the compound is without risk. The history of cannabinoid research shows that potency differences can amplify both intended and unintended responses. Regulatory agencies in several countries have noted similar patterns with other novel cannabinoids that reached markets before comprehensive safety data existed.

Photo by Sasun Bughdaryan on Unsplash

Documented and Inferred Adverse Effects

Side effects associated with THCP are expected to parallel those of THC but occur at lower doses or with greater intensity. Common reports include dizziness, dry mouth, rapid heart rate, sedation, anxiety, and paranoia. Because THCP activates CB1 receptors more strongly, even modest amounts may produce pronounced impairment or discomfort. A 2025 case report described an individual who developed acute psychosis lasting forty-eight hours after ingesting eight milligrams of delta-9-THCP. The episode culminated in a self-inflicted injury. The authors noted that the patient had prior experience with THC yet still experienced severe effects from this newer compound.

Longer duration of action has also appeared in anecdotal accounts, with some users describing effects persisting beyond twenty-four hours. No systematic data yet confirm average duration or dose-response curves in humans. The potential for accidental overconsumption therefore stands as a practical concern, particularly with products whose labeling may not reflect actual THCP content.

Regulatory Context Across Jurisdictions

Legal status for THCP varies widely. In the United States, many products containing THCP are marketed as hemp-derived under the 2018 Farm Bill framework, though enforcement actions and state-level restrictions have increased. European regulators have moved more quickly to classify novel cannabinoids under existing controlled-substance rules in several member states. These differences create uneven consumer protections and complicate efforts to track adverse events globally.

Product quality adds another layer of uncertainty. Laboratory testing of commercial cannabinoid products has repeatedly revealed discrepancies between labeled and actual concentrations. Without standardized manufacturing or third-party verification requirements in many markets, users cannot reliably determine how much THCP they are ingesting.

Photo by Viktor Forgacs on Unsplash

Implications for Research and Policy

The pattern observed with THCP mirrors earlier episodes in cannabinoid science. New compounds emerge from plant analysis or synthesis, receptor studies indicate heightened activity, and market availability precedes clinical evaluation. Policymakers face the recurring question of how to balance innovation with public health safeguards when data remain incomplete.

Further investigation would benefit from pharmacokinetic studies, dose-escalation trials in controlled settings, and post-market surveillance of adverse events. Until such work is completed, individuals considering THCP encounter a risk profile that is plausible but incompletely characterized. The compound's greater receptor affinity supplies a mechanistic basis for amplified effects, yet the precise magnitude of those effects in diverse populations remains unknown.

The original 2019 study provides the primary laboratory foundation for current understanding. A separate 2025 case report supplies the most detailed published account of a serious adverse reaction in a human user. Both documents underscore the gap between receptor-level potency and real-world safety data.